Project Grant R21CA283132
Award Date
9/15/23
Completion Date
8/31/25
Dollars Obligated
$415K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Virginia, USA
Similar Awards
This $399,187 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research at Virginia Commonwealth University to study the role of ATG16L1 isoforms in colorectal cancer health disparities. The key objectives are to: 1) Determine whether the ATG16L1 T300T isoform, which is more predominant in African Americans, promotes more aggressive colorectal tumor growth and metastasis compared to the A300A isoform found more in...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), will support research conducted by Thomas Jefferson University to investigate genomic factors contributing to racial disparities in metastatic prostate cancer outcomes. The key products or services to be delivered under this $156,000 award include whole-exome sequencing of circulating tumor cells (CTCs) from paired Black and White patients with metastatic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $632,319 to the Van Andel Research Institute (VAI) to conduct research on the mechanisms of DNA methylation signaling and dysregulation in colon cancer. The 5-year project, starting on July 2, 2024, aims to characterize the ubiquitin signaling network that regulates DNA methylation inheritance, investigate how overexpression of the E3 ubiquitin ligase UHRF1...
This $2,136,715 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) is focused on harnessing DNA methylation in peripheral blood to improve colorectal cancer prevention. The primary awardee, President and Fellows of Harvard College through its Harvard T.H. Chan School of Public Health, will lead the research effort. Key sub-awards have been made to Dana-Farber Cancer Institute and Boston University to contribute...
This Project Grant award of $192,610 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support a study to evaluate the impact of social determinants of health (SDOH) on early-onset colorectal cancer (EOCRC) diagnosis, treatment, and survival in Kentucky and Georgia. The primary objectives are to: 1) examine the association between SDOH and EOCRC diagnosis, stratified by age, sex, and race/ethnicity; and 2) assess how SDOH influence delays in the first...
The National Cancer Institute (NCI) awarded a $5,151,564 Project Grant under the Cancer Centers Support Grants (CFDA 93.397) program to the Fred Hutchinson Cancer Center in Seattle, WA to conduct a Translational Research Program in Colorectal Cancer Disparities. The program aims to reduce persistent racial and ethnic disparities in colorectal cancer (CRC) incidence, mortality, and morbidity, particularly among African American and Alaska Native populations. Key products and services include:...
This federal Project Grant award of $334,233, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program, will support a comprehensive research study examining disparities in novel cancer therapies, the joint effects of cancer treatment and comorbidities, and multi-level contributors to cancer survival outcomes. The University of South Carolina, the prime awardee, will conduct innovative data linkages between the state cancer registry,...
This Project Grant award from the National Cancer Institute (NCI) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program (CFDA 93.353) provides $1,165,096.00 to the Sloan-Kettering Institute for Cancer Research to investigate the social genomic mechanisms linking structural racism, perceived discrimination, and breast cancer survival. The key products and services to be delivered under this 5-year award include: 1) Defining the contributions of objective structural racism and...
The National Cancer Institute (NCI) awarded a $439,367 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Board of Regents of the University of Nebraska, through its University of Nebraska Medical Center (UNMC) Division. The grant, titled "Assessment of Strategies for Targeting Transcriptional Co-Activators in Colorectal Cancer," aims to investigate the role of PGC-1 family proteins, specifically PGC-1B, in promoting the survival of colorectal...
This $192,433 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program supports a research project to pilot an implementation strategy for increasing the use of mainstream genetic testing (MGT) for colorectal cancer (CRC) patients. The University of Alabama at Birmingham (UAB) will assess barriers to implementing MGT among healthcare providers and institutional stakeholders, as well as patient perceptions, to inform a multi-level...